Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic.
Scand Cardiovasc J. 2020 Oct;54(5):306-314. doi: 10.1080/14017431.2020.1781239. Epub 2020 Jun 18.
Development of right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation remains a leading cause of perioperative morbidity, end-organ dysfunction and mortality. The objective of this study was to investigate whether the etiology of HF (ischemic HF versus non-ischemic HF) affects the risk of RVF within admission for LVAD implantation and during long-term follow-up. Between January 2011 and June 27, 2018, 3536 patients were prospectively enrolled into EUROMACS registry. Adult patients (>18 years) who received a first time LVAD were included. When excluding patients with congenital, restrictive, hypertrophic, valvular cardiomyopathies, and myocarditis the total population consisted of 2404 patients. The total cohort consists of 2404 patients. Mean age were 55 years and predominantly male sex [2024 (84.2%)]. At the time of LVAD implantation 1355 (56.4%) patients had ischemic HF and 1049 (43.6%) patients had non-ischemic HF. The incidence of RVF was significantly increased in the non-ischemic HF group in the adjusted model ( = .026). The relative risk difference for RVF in patients with non-ischemic HF was in the adjusted model increased by an absolute value of 5.1% (95% CI: 0.61-9.6). In the ischemic HF group 76 patients (13.4%) developed late RVF and 62 patients (14.8%) in the non-ischemic HF group ( = .56). No differences in occurrence of RVF between HF etiology was observed after 2 and 4 years of follow-up, respectively (crude: = .25, adjusted (sex and age) = .2 and crude: = .59, adjusted (sex and age) = .44). Patients with non-ischemic HF undergoing LVAD had an increased incidence of early RVF compared to patients with ischemic HF in a large European population. During follow-up after discharge 14% patients developed RVF. We recommend HF etiology to be considered in identifying patients who are at risk for postoperative RVF after LVAD implantation.
在左心室辅助装置(LVAD)植入后,右心室衰竭(RVF)的发展仍然是围手术期发病率、终末器官功能障碍和死亡率的主要原因。本研究的目的是探讨 HF 的病因(缺血性 HF 与非缺血性 HF)是否会影响 LVAD 植入时住院期间和长期随访期间 RVF 的风险。
2011 年 1 月至 2018 年 6 月 27 日,3536 例患者前瞻性纳入 EUROMACS 登记处。纳入首次接受 LVAD 的成年患者(>18 岁)。当排除先天性、限制型、肥厚型、瓣膜性心肌病和心肌炎患者后,总人群由 2404 例患者组成。
总队列由 2404 例患者组成。平均年龄为 55 岁,主要为男性[2024(84.2%)]。在 LVAD 植入时,1355 例(56.4%)患者为缺血性 HF,1049 例(43.6%)患者为非缺血性 HF。在调整模型中,非缺血性 HF 组 RVF 的发生率显著增加( = .026)。在调整模型中,非缺血性 HF 患者 RVF 的相对风险差异增加了绝对值 5.1%(95%CI:0.61-9.6)。在缺血性 HF 组中,76 例(13.4%)患者出现晚期 RVF,而非缺血性 HF 组中 62 例(14.8%)患者出现 RVF( = .56)。在 2 年和 4 年的随访中,HF 病因之间的 RVF 发生率无差异(未调整: = .25,调整(性别和年龄): = .2,未调整: = .59,调整(性别和年龄): = .44)。
在欧洲大型人群中,与缺血性 HF 患者相比,接受 LVAD 的非缺血性 HF 患者 RVF 的发生率早期增加。在出院后的随访期间,14%的患者出现 RVF。我们建议在识别 LVAD 植入术后发生术后 RVF 风险的患者时,应考虑 HF 的病因。